The numerous beneficial effects of GIPR signal modification render the peptide an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, drug-induced nausea and both bone and neurodegenerative disorders. The gene discussed is GIPR; the disease is obesity due to melanocortin 4 receptor deficiency.